Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer.

  PMID 42193276 · PMC13203762 · Biomedicines · 2026 · 8 claims · 8 setups

  Full-text index only

  PARPi + ARPi combinations are effective in ARPi-sensitive (C4-2B) and ARPi-resistant (AbiR, MDVR) prostate cancer models, but provide the greatest benefit in ARPi-sensitive cells

  c4-2b cck-8 morphology western

• Decoding the tumor microenvironment and molecular mechanism: unraveling cervical cancer subpopulations and prognostic signatures through scRNA-Seq and bulk RNA-seq analyses.

  PMID 38482016 · PMC10933018 · Frontiers in immunology · 2024 · 8 claims · 8 setups

  Has reproduction · 80

  C3 PLP2+ Tumor Epithelial Progenitor Cells are a noteworthy subpopulation exerting a pivotal influence on CC differentiation and progression

  cervical tcga siha scrna-seq bulk rt-qpcr

• Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.

  PMID 33634984 · PMC7882098 · Clinical and translational medicine · 2021 · 8 claims · 8 setups

  Has reproduction · 85

  JMJD6 is identified as a potent epigenetic vulnerability/fitness gene in RCC by integrating GeCK CRISPR screening data with TCGA-KIRC epigenetic regulator survival analysis

  pan-cancer tcga-kirc rcc balb crispr rna-seq mtt

• MAZ-mediated tumor progression and immune evasion in hormone receptor-positive breast cancer: Targeting tumor microenvironment and PCLAF+ subtype-specific therapy.

  PMID 39805182 · PMC11780959 · Translational oncology · 2025 · 6 claims · 8 setups

  Full-text index only

  A C3 PCLAF+ tumor cell subtype identified by scRNA-seq shows high proliferation/differentiation potential and is linked to aggressive tumor behavior and poor prognosis in HR+BC

  hr+bc mda-mb-361 tcga scrna-seq cellchat pyscenic

• Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy.

  PMID 41494534 · PMC12866099 · Cell reports. Medicine · 2026 · 8 claims · 8 setups

  Full-text index only

  VPNS@P selectively accumulates in immune cells within atherosclerotic plaques (predominantly macrophages and monocytes, partly T and B cells) with minimal off-target uptake by non-immune vascular cells

  vpns@p cell-free raw264.7 bone-marrow-derived tem ros-scavenging cck-8

• Identification of a novel lncRNA prognostic signature and analysis of functional lncRNA AC115619.1 in hepatocellular carcinoma.

  PMID 37614318 · PMC10442647 · Frontiers in pharmacology · 2023 · 8 claims · 8 setups

  Has reproduction · 87

  A six-lncRNA prognostic signature (LINC02428, LINC02163, AC008549.1, AC115619.1, CASC9, LINC02362) predicts overall survival in HCC patients

  hcc tcga paired snu-449 lncrna sequencing univariate

• Constructing an APOBEC-related gene signature with predictive value in the overall survival and therapeutic sensitivity in lung adenocarcinoma.

  PMID 37954334 · PMC10637964 · Heliyon · 2023 · 8 claims · 8 setups

  Has reproduction · 88

  APOBEC family genes are differentially expressed across cancer types and tissues, with APOBEC3B being the most aberrantly upregulated gene in most cancers including LUAD

  tcga tcga-luad beas-2b rna-seq somatic gene